Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:NGNE NASDAQ:NTLA NASDAQ:RAPP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$26.98-0.8%$29.76$22.24▼$46.00$1.62B0.581.35 million shs1.08 million shsNGNENeurogene$32.61+12.7%$22.80$12.97▼$37.27$451.93M1.69174,899 shs341,174 shsNTLAIntellia Therapeutics$13.85+4.1%$13.65$6.83▼$28.25$1.60B1.937.35 million shs3.80 million shsRAPPRapport Therapeutics$37.06+4.1%$31.86$7.73▼$42.27$1.70B0.82337,646 shs213,378 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals-0.85%-3.81%-22.47%+1.54%-4.80%NGNENeurogene+12.66%+23.13%+59.28%+99.18%+149.85%NTLAIntellia Therapeutics+4.06%+11.33%+4.14%+24.89%+91.03%RAPPRapport Therapeutics+4.13%+12.30%+14.45%+45.05%+256.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$26.98-0.8%$29.76$22.24▼$46.00$1.62B0.581.35 million shs1.08 million shsNGNENeurogene$32.61+12.7%$22.80$12.97▼$37.27$451.93M1.69174,899 shs341,174 shsNTLAIntellia Therapeutics$13.85+4.1%$13.65$6.83▼$28.25$1.60B1.937.35 million shs3.80 million shsRAPPRapport Therapeutics$37.06+4.1%$31.86$7.73▼$42.27$1.70B0.82337,646 shs213,378 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals-0.85%-3.81%-22.47%+1.54%-4.80%NGNENeurogene+12.66%+23.13%+59.28%+99.18%+149.85%NTLAIntellia Therapeutics+4.06%+11.33%+4.14%+24.89%+91.03%RAPPRapport Therapeutics+4.13%+12.30%+14.45%+45.05%+256.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.45Hold$41.5654.02% UpsideNGNENeurogene 2.75Moderate Buy$67.00105.49% UpsideNTLAIntellia Therapeutics 2.35Hold$20.0945.03% UpsideRAPPRapport Therapeutics 3.00Buy$54.8347.96% UpsideCurrent Analyst Ratings BreakdownLatest NGNE, AGIO, NTLA, and RAPP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2026AGIOAgios Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$39.00 ➝ $36.004/28/2026NTLAIntellia Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$8.00 ➝ $9.004/28/2026NGNENeurogene GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$69.004/28/2026NTLAIntellia Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/28/2026NGNENeurogene GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/28/2026NTLAIntellia Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$48.00 ➝ $58.004/28/2026NTLAIntellia Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$28.00 ➝ $30.004/27/2026NTLAIntellia Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$35.004/27/2026NTLAIntellia Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$11.00 ➝ $15.004/27/2026NTLAIntellia Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$7.00 ➝ $13.004/27/2026NTLAIntellia Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $30.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$54.03M29.70N/AN/A$18.65 per share1.45NGNENeurogeneN/AN/AN/AN/A$17.10 per shareN/ANTLAIntellia Therapeutics$67.67M24.65N/AN/A$5.80 per share2.39RAPPRapport TherapeuticsN/AN/AN/AN/A$10.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals-$412.78M-$7.25N/AN/AN/A-639.84%-34.11%-31.66%N/ANGNENeurogene-$90.35M-$4.24N/AN/AN/AN/A-32.99%-30.39%5/7/2026 (Estimated)NTLAIntellia Therapeutics-$412.69M-$3.83N/AN/AN/A-609.85%-56.81%-45.34%5/14/2026 (Estimated)RAPPRapport Therapeutics-$111.48M-$2.86N/AN/AN/AN/A-28.85%-27.27%5/7/2026 (Estimated)Latest NGNE, AGIO, NTLA, and RAPP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026NTLAIntellia Therapeutics-$0.92N/AN/AN/A$13.81 millionN/A5/7/2026Q1 2026NGNENeurogene-$1.2963N/AN/AN/AN/AN/A5/7/2026Q1 2026RAPPRapport Therapeutics-$0.6241N/AN/AN/A$7.50 millionN/A4/29/2026Q1 2026AGIOAgios Pharmaceuticals-$1.81-$1.69+$0.12-$1.69$13.30 million$20.75 million3/24/2026Q4 2025NGNENeurogene-$1.20-$1.12+$0.08-$1.12N/AN/A3/10/2026Q4 2025RAPPRapport Therapeutics-$0.65-$0.72-$0.07-$0.72N/AN/A2/26/2026Q4 2025NTLAIntellia Therapeutics-$0.99-$0.83+$0.16-$0.83$12.17 million$23.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.1913.59NGNENeurogeneN/A16.5616.56NTLAIntellia TherapeuticsN/A5.085.08RAPPRapport TherapeuticsN/A26.1726.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/ANGNENeurogene52.37%NTLAIntellia Therapeutics88.77%RAPPRapport TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals5.40%NGNENeurogene11.64%NTLAIntellia Therapeutics3.10%RAPPRapport Therapeutics13.57%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39059.47 million56.26 millionOptionableNGNENeurogene9015.62 million13.80 millionOptionableNTLAIntellia Therapeutics600120.46 million116.73 millionOptionableRAPPRapport TherapeuticsN/A47.81 million41.32 millionN/ANGNE, AGIO, NTLA, and RAPP HeadlinesRecent News About These CompaniesRapport Therapeutics Insiders Added US$1.61m Of Stock To Their HoldingsApril 30, 2026 | finance.yahoo.comModalités de mise à disposition du rapport financier annuel 2025April 30, 2026 | globenewswire.comMISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025April 30, 2026 | globenewswire.comRapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on ThursdayApril 30, 2026 | marketbeat.comRapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Buy" from BrokeragesApril 29, 2026 | marketbeat.comRapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials NearApril 27, 2026 | fool.comRapport Therapeutics, Inc. ($RAPP) CEO 2025 Pay RevealedApril 23, 2026 | quiverquant.comQBTIG Research Reaffirms "Buy" Rating for Rapport Therapeutics (NASDAQ:RAPP)April 23, 2026 | marketbeat.comInsider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells 20,225 Shares of StockApril 22, 2026 | insidertrades.comRapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology ...April 21, 2026 | finance.yahoo.comInsider Selling: Rapport Therapeutics (NASDAQ:RAPP) Major Shareholder Sells 426,005 Shares of StockApril 21, 2026 | marketbeat.comKrishnaswamy Yeleswaram Sells 20,225 Shares of Rapport Therapeutics (NASDAQ:RAPP) StockApril 21, 2026 | marketbeat.comRapport Therapeutics advances RAP-219 after strong Phase 2a dataApril 21, 2026 | tipranks.comRapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual MeetingApril 21, 2026 | globenewswire.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Down 4.2% - Here's What HappenedApril 20, 2026 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Sees Unusually-High Trading Volume - Still a Buy?April 17, 2026 | marketbeat.comRapport Therapeutics Inc.April 17, 2026 | barrons.comRapport Therapeutics (NASDAQ:RAPP) Insider Sells $17,490.00 in StockApril 15, 2026 | insidertrades.comRapport Therapeutics (NASDAQ:RAPP) Insider Krishnaswamy Yeleswaram Sells 500 SharesApril 14, 2026 | marketbeat.comInsider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells 9,165 Shares of StockApril 14, 2026 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Insider Sells $357,816.00 in StockApril 14, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 2026These 3 ETFs Are Suitable for Ultra-Bearish InvestorsBy Nathan Reiff | April 11, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026NGNE, AGIO, NTLA, and RAPP Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$26.98 -0.23 (-0.85%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$27.00 +0.02 (+0.08%) As of 04:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Neurogene NASDAQ:NGNE$32.60 +3.67 (+12.66%) Closing price 05/6/2026 03:59 PM EasternExtended Trading$32.38 -0.22 (-0.67%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Intellia Therapeutics NASDAQ:NTLA$13.85 +0.54 (+4.06%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$13.95 +0.10 (+0.72%) As of 04:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Rapport Therapeutics NASDAQ:RAPP$37.06 +1.47 (+4.13%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$36.35 -0.71 (-1.92%) As of 04:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Years in the Making, AMD’s Upside Movement Has Just Begun Capital One’s Big Bet Faces Rising Credit Risk Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
